Clinical Genomics Uppsala frequently engages in collaborative projects with industry and academia. Our contribution to these partnerships can for example include:

  • Development of novel diagnostic methods
  • Testing of new products
  • Characterization of patient material

Please contact us if you are interested in initiating a new collaborative project with us.

Staff in the laboratory

Photo: Mikael Wallerstedt

Examples of past and present collaborative projects

Ultrasensitive variant detection

In collaboration with Rarity Bioscience, we are evaluating the clinical potential of the superRCA method for ultrasensitive variant detection. We currently conduct a study where the method is used for early detection of relapse in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

We also collaborate with Prof. Eva Hellström-Lindberg and Dr. Magnus Tobiasson on a clinical trial focusing on sensitive follow-up after stem-cell transplantation in myelodysplastic syndrome (MDS) using digital droplet PCR.

Related publication

Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Ejerblad E, Olesen G, Björklund A, Olsnes Kittang A, Werlenius O, Lorentz F, Rasmussen B, Cammenga J, Weber D, Lindholm C, Wiggh J, Dimitriou M, Moen AE, Yip Lundström L, von Bahr L, Baltzer-Sollander K, Jädersten M, Kytölä S, Walldin G, Ljungman P, Groenbaek K, Mielke S, Jacobsen SEW, Ebeling F, Cavelier L, Smidstrup Friis L, Dybedal I, Hellström-Lindberg E. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2024

Tumor mutation burden in solid tumors

In collaboration with Bristol-Myers Squibb and Illumina, we have evaluated broad gene panels that allow calculation of tumor mutation burden (TMB) in solid tumors. A high TMB is a biomarker for patients likely to respond well to immunotherapy.

Resistance mutation testing in leukemia

We collaborate with Incyte and several European laboratories to standardize and establish NGS-based resistance mutation testing in leukemia. We take part in a Nordic study aiming to monitor mutations in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).